NCT03460977 2026-03-13
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
Clinical Trials
9 trialsNCT06787131 2025-12-05
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
Lomond Therapeutics Holdings, Inc.
Phase 1 Completed
NCT04067336 2025-11-10
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1/2 Recruiting
NCT02875223 2025-04-20
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Celgene
Phase 1 Terminated
NCT04537715 2025-02-19
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Phase 1 Completed
NCT05602597 2024-03-06
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
Hutchmed
Phase 1 Completed
NCT05720767 2023-03-01
HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
Hutchmed
Phase 1 Completed
NCT02253420 2020-12-14
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
Bayer
Phase 1 Completed
NCT02259010 2019-09-20
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Takeda
Phase 1 Completed